GlassScriptPhysician profile
Erik K Johnson
NPI 1679545727
$9,594.76
in general payments reported to CMS, 2019-2025
36 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $1,063 · 2021: $1,296 · 2022: $1,385 · 2023: $1,664 · 2024: $1,408 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,399.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,217.45 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $984.66 | 2019-2025 | |
| Novo Nordisk INC | $870.89 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $743.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $737.82 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $591.43 | 2019-2023 | |
| Glaxosmithkline, LLC. | $485.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $453.92 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.08 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $360.12 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $330.35 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $314.65 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $302.87 | 2019-2025 | |
| Astellas Pharma US INC | $299.94 | 2019-2024 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $259.74 | 2020-2025 | Nexletol |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $151.11 | 2019-2020 | |
| Vertos Medical, INC. | $128.24 | 2022-2023 | Mild Device Kit |
| Abbvie INC. | $117.28 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $106.44 | 2021-2023 | Livalo |
| Exact Sciences Corporation | $103.02 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $90.83 | 2021-2025 | |
| Sanofi Pasteur INC. | $86.59 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.63 | 2022 | |
| Abbott Laboratories | $65.43 | 2021-2023 | Freestyle Libre 2 |
| Lundbeck LLC | $59.41 | 2020-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $54.61 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $38.29 | 2019-2021 | |
| Linus Health, INC. | $22.56 | 2023 | |
| Boston Scientific Corporation | $22.46 | 2024 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $20.37 | 2023 | Vpriv |
| Almatica Pharma LLC | $18.93 | 2023 | Loreev Xr |
| Circassia INC. | $17.44 | 2019 | |
| Vivus LLC | $16.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.32 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.69 | 2019 | |
| Dexcom, INC. | $13.90 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.